ANN ARBOR, Mich., Feb. 8, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (Amex:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that an abstract on the
Company’s pivotal clinical trial of its zinc and cysteine-based
product candidate being evaluated in patients with Alzheimer’s
disease and mild cognitive impairment has been accepted for
presentation at the 2011 American Academy of Neurology Annual
Meeting in April. The abstract will provide top line clinical trial
results, as well as the rationale and design of the pivotal
study.
Diana Pollock, M.D., Lead Principal Investigator of the trial at
Morton Plant Neuroscience Institute on the campus of Morton Plant
Hospital, is the first author on the abstract titled “Clinical
Trial Results of the First Controlled Clinical Trial of Zinc-Based
Therapy for Alzheimer’s Disease and Mild Cognitive Impairment.” The
poster presentation will be held from 2:00 to 6:30 p.m. on April
14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. Due
to conference restrictions with regard to the embargo policy
relating to clinical trial results, Adeona plans to present the
results of its pivotal clinical trial during this conference and
distribute a concurrent press release.
Adeona also announced that “reaZin™” has been
adopted as the new trademark for its zinc and cysteine-based oral
tablet currently under development as a prescription medical food
for the dietary management of Alzheimer’s disease and mild
cognitive impairment. Previously, Adeona’s zinc and cysteine-based
product candidate was called Zinthionein.
reaZin was selected as the new trademark as it is a
homophone to the word reason, a high level cognitive function
affected by Alzheimer’s disease that Adeona’s product candidate
seeks to address. In addition, the “Zin” root is suggestive of the
p
‘/>”/>
SOURCE
